Raymond James & Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $17.1K | Hold |
10,912
| – | – | ﹤0.01% | 3905 |
|
|
2024
Q2 | $18.3K | Buy |
10,912
+71
| +0.7% | +$119 | ﹤0.01% | 3851 |
|
|
2024
Q1 | $26K | Hold |
10,841
| – | – | ﹤0.01% | 3812 |
|
|
2023
Q4 | $16.6K | Hold |
10,841
| – | – | ﹤0.01% | 3725 |
|
|
2023
Q3 | $11.8K | Sell |
10,841
-232
| -2% | -$253 | ﹤0.01% | 3718 |
|
|
2023
Q2 | $25.4K | Buy |
+11,073
| New | +$25.4K | ﹤0.01% | 3702 |
|
|
2017
Q4 | – | Sell |
-33,829
| Closed | -$416K | – | 3338 |
|
|
2017
Q3 | $416K | Sell |
33,829
-1,025
| -3% | -$12.6K | ﹤0.01% | 2581 |
|
|
2017
Q2 | $573K | Buy |
34,854
+3,418
| +11% | +$56.2K | ﹤0.01% | 2330 |
|
|
2017
Q1 | $451K | Buy |
31,436
+1,053
| +3% | +$15.1K | ﹤0.01% | 2446 |
|
|
2016
Q4 | $420K | Buy |
30,383
+2,150
| +8% | +$29.7K | ﹤0.01% | 2427 |
|
|
2016
Q3 | $510K | Buy |
28,233
+6,293
| +29% | +$114K | ﹤0.01% | 2267 |
|
|
2016
Q2 | $315K | Sell |
21,940
-33
| -0.2% | -$474 | ﹤0.01% | 2381 |
|
|
2016
Q1 | $263K | Buy |
+21,973
| New | +$263K | ﹤0.01% | 2413 |
|